← Back to Search

Patients referred for 99mTc-pyrophosphate Single Photon Emission Computed Tomography for Transthyretin Amyloid Cardiomyopathy

N/A
Recruiting
Led By Leandro Slipczuk, MD
Research Sponsored by Montefiore Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
All adult patients referred for PYP SPECT at Montefiore Medical Center between 2014 and 2023
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up within the study time frame parameters of the retrospective review (between 2014 and 2023)
Awards & highlights

Study Summary

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a commonly undiagnosed and potentially fatal disease. Contemporary studies on this condition often underrepresent the female gender and diverse patient populations. This registry retrospectively evaluated patients referred for 99mTc-pyrophosphate (PYP) Single Photon Emission Computed Tomography (SPECT) between 2014 and 2023 at Montefiore-Einstein in the Bronx. The patient population is racially and ethnically diverse and with a high proportion of females. Demographic, clinical (e.g. comorbidities), laboratory, echocardiographic, hospitalization, and mortality data were collected for each patient.

Eligible Conditions
  • Transthyretin Amyloid Cardiomyopathy

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~within the study time frame parameters of the retrospective review (between 2014 and 2023)
This trial's timeline: 3 weeks for screening, Varies for treatment, and within the study time frame parameters of the retrospective review (between 2014 and 2023) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
ATTR-CM Diagnosis
Mortality
Secondary outcome measures
Heart failure hospitalizations
Total Hospitalizations

Trial Design

1Treatment groups
Experimental Treatment
Group I: Patients referred for 99mTc-pyrophosphate Single Photon Emission Computed TomographyExperimental Treatment1 Intervention
Patients with suspected transthyretin cardiac amyloidosis referred for 99mTc-pyrophosphate Single Photon Emission Computed Tomography

Find a Location

Who is running the clinical trial?

Montefiore Medical CenterLead Sponsor
441 Previous Clinical Trials
581,720 Total Patients Enrolled
Leandro Slipczuk, MDPrincipal InvestigatorMontefiore Medical Center

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Bronx Transthyretin Amyloid Cardiomyopathy Database
2023. "Bronx Transthyretin Amyloid Cardiomyopathy Database". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06257485.
~301 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top